Singapore markets open in 7 hours 59 minutes

Sesen Bio, Inc. (SESN)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.4945-0.0055 (-1.10%)
At close: 04:00PM EDT
0.4934 -0.00 (-0.22%)
After hours: 07:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.5000
Open0.5006
Bid0.4934 x 1800
Ask0.4944 x 900
Day's range0.4500 - 0.5200
52-week range0.3650 - 6.0400
Volume2,177,924
Avg. volume3,882,214
Market cap98.635M
Beta (5Y monthly)0.93
PE ratio (TTM)1.75
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Sesen Bio Reports First Quarter 2022 Financial Results and Business Update

    CAMBRIDGE, Mass., May 09, 2022--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2022. During the quarter, the Company continued to engage with the US Food and Drug Administration (FDA) to identify an anticipated regulatory path toward potential resubmission of a Biologics License Application (BLA) for Vicineum™ for the treatment

  • Business Wire

    Sesen Bio Provides Strategic Update

    CAMBRIDGE, Mass., May 03, 2022--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it has initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of the Company, a merger, acquisition or other business combination, a strategic par

  • Business Wire

    Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company’s Lead Product Candidate, Vicineum™

    CAMBRIDGE, Mass., February 28, 2022--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quarter and full year ended December 31, 2021. During the fourth quarter, the Company worked with the US Food and Drug Administration (FDA) to identify an anticipated regulatory path toward potential resubmission of a Biologics License Application (BLA) for the Compan